168 related articles for article (PubMed ID: 33808404)
1. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.
Hupa-Breier KL; Dywicki J; Hartleben B; Wellhöner F; Heidrich B; Taubert R; Mederacke YE; Lieber M; Iordanidis K; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808404
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
Park HJ; Han H; Oh EY; Kim SR; Park KH; Lee JH; Park JW
Sci Rep; 2019 Oct; 9(1):15601. PubMed ID: 31666643
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
5. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
6. Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.
Koullias E; Papavdi M; Athanasopoulos S; Mitrakou A; Deutsch M; Zoumpoulis P; Manesis E; Thanopoulou A; Koskinas J
Cureus; 2024 Feb; 16(2):e53813. PubMed ID: 38465109
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
8. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
Bahirat UA; Talwar R; Shenoy RR; Nemmani KVS; Goel RN
Med Mol Morphol; 2019 Mar; 52(1):36-43. PubMed ID: 29959534
[TBL] [Abstract][Full Text] [Related]
9. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.
Hossain MF; Khan NA; Rahman A; Chowdhury MFI; Bari S; Khan MA; Masud UW; Zakia UB; Paul SP; Tasnim N
Cureus; 2022 Aug; 14(8):e28367. PubMed ID: 36168335
[TBL] [Abstract][Full Text] [Related]
12. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
13. L-Selectin/CD62L is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men.
Drescher HK; Schippers A; Rosenhain S; Gremse F; Bongiovanni L; Bruin A; Eswaran S; Gallage SU; Pfister D; Szydlowska M; Heikenwalder M; Weiskirchen S; Wagner N; Trautwein C; Weiskirchen R; Kroy DC
Cells; 2020 Apr; 9(5):. PubMed ID: 32365632
[TBL] [Abstract][Full Text] [Related]
14. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
[TBL] [Abstract][Full Text] [Related]
15. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.
Griffett K; Welch RD; Flaveny CA; Kolar GR; Neuschwander-Tetri BA; Burris TP
Mol Metab; 2015 Apr; 4(4):353-7. PubMed ID: 25830098
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
Bahirat UA; Shenoy RR; Talwar R; Goel RN; Nemmani KVS
Biochem Biophys Res Commun; 2018 Jan; 495(2):1608-1613. PubMed ID: 29203247
[TBL] [Abstract][Full Text] [Related]
17. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.
Christensen CU; Glavind E; Thomsen KL; Kim YO; Heebøll S; Schuppan D; Hamilton-Dutoit S; Würtz Heegaard C; Grønbæk H
PLoS One; 2018; 13(3):e0192728. PubMed ID: 29522534
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
19. Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
Kimura T; Obata A; Shimoda M; Hirukawa H; Kanda-Kimura Y; Nogami Y; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
Diabetes Metab; 2018 Jun; 44(3):250-260. PubMed ID: 29525225
[TBL] [Abstract][Full Text] [Related]
20. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.
Ye D; Yang K; Zang S; Lin Z; Chau HT; Wang Y; Zhang J; Shi J; Xu A; Lin S; Wang Y
J Hepatol; 2016 Nov; 65(5):988-997. PubMed ID: 27266617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
